Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 9, Issue 13, Pages 2247-2258Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.9.13.2247
Keywords
ibritumomab tiuxetan; lenalidomide; lymphoma; rituximab; tositumomab
Categories
Funding
- the United States Public Health Service - National Institutes of Health (ISL) [R01 CA109335, R01CA122105]
- he Dwoskin Family Foundation
Ask authors/readers for more resources
Background: Constituting approximately 30% of lymphoid malignancies, diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults worldwide. The clinical and biologic heterogeneity that exists in DLBCL suggests that this entity might actually be comprised of several distinct neoplasms that could require different therapeutic approaches. DLBCL was considered incurable until combination chemotherapy became available. Objective: Current treatment strategies for the treatment of untreated and relapsed advanced-stage DLBCL are reviewed; novel treatments for DLBCL are discussed. Methods: Relevant literature was identified using the PubMed search engine and by reviewing abstracts from major conference proceedings. Results/conclusion: Recently, novel therapeutic strategies, including the incorporation of immunotherapy to combination chemotherapy, have improved outcome for patients with DLBCL with cure rates exceeding 50%, especially in younger patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available